Form 4 for LUCD Lucid Diagnostics Inc.
Accepted 2023-09-27 00:00:00 ET · period of report 2023-09-25 · accession 0001062993-23-018552 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-09-27 | 2023-09-25+ | LUCD | Lapidus Stanley | Dir | S - Sale | $1.45 | -29.9K | 101.6K | -23% | -$43.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2023-09-25 | S | D | 200 | $1.43 | 131,339 | D | — | — | (F2) Represents shares the Reporting Person received as a restricted stock grant under the Issuer's 2018 Equity Plan. Such grant was 169,320 shares of common stock, 50% of which vested September 20, 2022 and 50% of which vested September 20, 2023. (F3) The reported sales of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. |
| 2 | Common | Common stock | 2023-09-26 | S | D | 10,000 | $1.47 | 121,339 | D | — | — | (F2) Represents shares the Reporting Person received as a restricted stock grant under the Issuer's 2018 Equity Plan. Such grant was 169,320 shares of common stock, 50% of which vested September 20, 2022 and 50% of which vested September 20, 2023. (F3) The reported sales of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. |
| 3 | Common | Common stock | 2023-09-26 | S | D | 10,000 | $1.43 | 111,339 | D | — | — | (F2) Represents shares the Reporting Person received as a restricted stock grant under the Issuer's 2018 Equity Plan. Such grant was 169,320 shares of common stock, 50% of which vested September 20, 2022 and 50% of which vested September 20, 2023. (F3) The reported sales of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. |
| 4 | Common | Common stock | 2023-09-26 | S | D | 9,747 | $1.45 | 101,592 | D | — | — | (F2) Represents shares the Reporting Person received as a restricted stock grant under the Issuer's 2018 Equity Plan. Such grant was 169,320 shares of common stock, 50% of which vested September 20, 2022 and 50% of which vested September 20, 2023. (F3) The reported sales of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023. |